Get the Stockscreener App
268.54
0.54%
-1.46
After Hours:
268.28
-0.26
-0.10%
Krystal Biotech Inc stock is traded at $268.54, with a volume of 246.24K.
It is down -0.54% in the last 24 hours and up +8.61% over the past month.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
See More
Previous Close:
$270.00
Open:
$270.01
24h Volume:
246.24K
Relative Volume:
0.85
Market Cap:
$7.90B
Revenue:
$389.13M
Net Income/Loss:
$204.83M
P/E Ratio:
39.24
EPS:
6.8443
Net Cash Flow:
$188.91M
1W Performance:
+1.64%
1M Performance:
+8.61%
6M Performance:
+39.15%
1Y Performance:
+58.78%
1-Day Range:
$262.40
$271.05
1-Week Range:
$252.30
$275.75
52-Week Range:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
268.54 | 7.95B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech Inc stock (US5012681064): Is its gene therapy pipeline strong enough to unlock new u - AD HOC NEWS
Book value per share of Krystal Biotech Inc Unsponsored BDR – BMFBOVESPA:K1YS34 - TradingView — Track All Markets
Total equity of Krystal Biotech Inc Unsponsored BDR – BMFBOVESPA:K1YS34 - TradingView — Track All Markets
Krystal Biotech (HAM:4KB) Cyclically Adjusted Price-to-FCF : (As of Apr. 11, 2026) - GuruFocus
Krystal Biotech (NASDAQ:KRYS) - intelligentinvestor.com.au
Price-Driven Insight from (KRYS) for Rule-Based Strategy - Stock Traders Daily
Krystal Biotech (HAM:4KB) Gross Property, Plant and Equipment : €161.7 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - GuruFocus
Krystal Biotech Inc (HAM:4KB) Competitors 2026 - GuruFocus
Krystal Biotech (HAM:4KB) Net Income (Continuing Operations) : €177.8 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (HAM:4KB)Valuation Measures & Financial Statistics - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Krystal Biotech Inc (HAM:4KB) Dividend - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Krystal Biotech Inc (HAM:4KB) Stock Today? - GuruFocus
Krystal Biotech Inc Stock Operating Data - GuruFocus
Krystal Biotech Inc (HAM:4KB) Valuation - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock News, Headlines & Updates - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock Earnings Transcripts - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock Price, Trades & News - GuruFocus
KRYS Technical Analysis | Trend, Signals & Chart Patterns | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Layoff Watch: Can Krystal Biotech Inc weather a recession2026 PreEarnings & Fast Gain Stock Trading Tips - baoquankhu1.vn
Could This Under-the-Radar Healthcare Stock Set You Up for Life? - AOL.com
KRYS | Krystal Biotech, Inc. Common Executive Compensation - Quiver Quantitative
Krystal Biotech, Inc. ($KRYS) CEO 2025 Pay Revealed - Quiver Quantitative
KRYS PE Ratio & Valuation, Is KRYS Overvalued - Intellectia AI
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
[DEF 14A] Krystal Biotech, Inc. Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion - simplywall.st
KRYS News & Events - intellectia.ai
BSP:K1YS34 PB Ratio: 0.20 — 96% Below Median - GuruFocus
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
(KRYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Krystal Biotech stock price forecast: consolidation likely as KRYS hovers near key support and down 2.39% - Traders Union
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness - finance.yahoo.com
Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Wolfe Research - Defense World
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PB Ratio : (As of Apr. 01, 2026) - GuruFocus
Krystal Biotech (BSP:K1YS34) EBITDA per Share : R$30.92 (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross Property, Plant and Equipment : R$1,033 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
Q3 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Krystal Biotech (BSP:K1YS34) Shiller PE Ratio : (As of Mar. 28, 2026) - GuruFocus
BSP:K1YS34 Pretax Margin %: 47.74% — 45% Above Median - GuruFocus
Krystal Biotech (BSP:K1YS34) Unearned Premiums - GuruFocus
BSP:K1YS34 Graham Number: R$439.15 — 14786% Above Median - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Dividend - GuruFocus
Krystal Biotech Inc FDA Approval Call Transcript - GuruFocus
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):